Cellular Biology News and Research

RSS

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and Tulane University, today announced a major extension of the collaborative effort to combat viral hemorrhagic fever (VHF), an effort that will generate an additional $800,000 in contract revenue for Corgenix over the life of the contract.

9 Feb 2010

Mapping of human genome modification during embryonic development

Scientists at The Genome Institute of Singapore (GIS) and The Scripps Research Institute (TSRI) led an international effort to build a map that shows in detail how the human genome is modified during embryonic development.

4 Feb 2010

New discovery lays foundation for development of new anti-HIV drugs

A team of scientists at The Scripps Research Institute has identified two compounds that act on novel binding sites for an enzyme used by the human immunodeficiency virus (HIV), the virus that causes AIDS.

4 Feb 2010

New bioanalytical methods have potential for investigative and screening applications

The Springer journal Analytical and Bioanalytical Chemistry (ABC) has chosen Jean-Philippe Frimat (29) as the recipient of its Best Paper Award 2009. Frimat is the lead author of a paper in ABC on plasma stencilling methods for cell patterning.

3 Feb 2010

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Repros Therapeutics Inc. today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug Application for the study of oral Androxal® in the treatment of hypogonadal men with Type II Diabetes (T2D) with a Phase IIa trial.

3 Feb 2010

Decreased release of neurotransmitter acetylcholine contributes to heart failure

Scientists at the Robarts Research Institute at The University of Western Ontario, working in collaboration with researchers in Brazil, have used a unique genetically-modified mouse line to reveal a previously unidentified mechanism contributing to heart failure.

2 Feb 2010

Blocking action of key protein boosts immune 'memory' to prevent or clear viral infection

Researchers at The Scripps Research Institute have discovered a potential new way to stimulate the immune system to prevent or clear a viral infection. By blocking the action of a key protein in the mouse immune system, they were able to boost immune "memory" in those mice-work that may one day help doctors increase the effectiveness of human vaccines designed to prevent viral infections.

28 Jan 2010

Blocking CRF may prevent excessive alcohol consumption

A team of scientists from The Scripps Research Institute has found that a specific stress hormone, the corticotropin-releasing factor (CRF), is key to the development and maintenance of alcohol dependence in animal models.

28 Jan 2010

MDRNA granted Chinese patent for use of nucleic acids in cancer treatment

MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that the State Intellectual Property Office of the People's Republic of China (PRC) has issued a Notification of Granting Patent Rights for PRC 200480018784 which includes the use of nucleic acids, e.g., an siRNA, for the treatment of cancer. The patent describes modulation of claudins, which are proteins implicated in tumor progression and metastasis.

27 Jan 2010

FDA approves Novo Nordisk's Victoza for type 2 diabetes

Novo Nordisk, a global healthcare company, announced today the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza® (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

27 Jan 2010

MDRNA to receive European patent for its intranasal insulin formulation

MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that the European Patent Office intends to grant a patent for application EP06826368 covering formulations for the intranasal delivery of rapid acting insulin, and its use for the treatment of diabetes.

21 Jan 2010

Researchers propose a new model for breast cell differentiation

A study by researchers at Tufts University School of Medicine, the Sackler School of Graduate Biomedical Sciences at Tufts, and Tufts Medical Center improves our current understanding of the origins of breast cancer. The

19 Jan 2010

Interdisciplinary nature of biological research triggers changes to JBC's publishing policies

The Journal of Biological Chemistry's editors are unveiling this week a number of changes to the journal's publishing policies. They say the changes are in response to the increasingly interdisciplinary nature of biological research and will help the journal better meet the evolving needs of the scientific community.

19 Jan 2010

Scripps Research scientists produce chemically complex compound

In 1993 researchers discovered a chemical compound in a sponge off Palau, an island nation in the Pacific Ocean, that has shown anticancer, antibacterial, and antifungal pharmaceutical promise. But that wasn't its greatest allure, at least not for chemists.

13 Jan 2010

Work provides new insight into potential therapeutic treatments for cancer diseases

An enzyme that normally helps break down stored fats goes into overdrive in some cancer cells, making them more malignant, according to new findings by a team at The Scripps Research Institute.

13 Jan 2010

Sorrento Therapeutics, Scripps Research Institute announce antibody development collaboration

Sorrento Therapeutics, Inc. today announced an antibody discovery and development collaboration with The Scripps Research Institute, La Jolla, CA. Under the terms of the agreement, Sorrento Therapeutics obtains an exclusive, worldwide license to the Institute's novel technology, based on quorum sensing, for the prevention and treatment of Staphylococcus aureus ('Staph') infections, including Methicillin-resistant Staph. aureus (MRSA).

12 Jan 2010

Acetylon Pharmaceuticals to utilise additional funding in multiple myeloma drug development

Acetylon Pharmaceuticals, Inc. announced today that it has closed on a $2 million investment from a new undisclosed private investor to bring its total financing to $9.25 million. This new investment will convert to stock in the next substantial round of preferred equity financing.

9 Jan 2010

Researchers identify new approach to eliminate side effects of drugs

Researchers at the Stanford University School of Medicine have taken an early step toward identifying a new approach to drug discovery that may eventually yield drugs with fewer side effects.

7 Jan 2010

Biological Industries named exclusive distributor of ATCC products in Israel

ATCC today announced a distribution and development partnership with Biological Industries Ltd. to become the exclusive distributor of ATCC products in Israel. The Israel-based organization is now the newest member of the global network of distributors for ATCC.

5 Jan 2010

Research may point to more effective therapeutic targets for prion diseases

Scientists from The Scripps Research Institute have determined for the first time that prions, bits of infectious protein devoid of DNA or RNA that can cause fatal neurodegenerative disease, are capable of Darwinian evolution.

4 Jan 2010